The Basics
- State research and development (R&D) credits can provide significant tax savings beyond the federal R&D credit.
- While many states start with the federal definition of qualified research expenses (QREs),they apply their own rules governing where research must occur, how the credit is calculated, when a claim must be filed and whether the resulting benefit can actually be used or monetized.
- Because many states have recently expanded or redesigned their R&D credit programs, companies should evaluate where research is performed and understand how federal and state rules interact before filing returns.
______________________________________________________________________________________________
State R&D Tax Credits: Distinct from Federal Rules and State to State
For many businesses, the federal R&D credit has historically served as the starting point — and often the ending point — of the R&D incentive analysis. That approach is becoming increasingly incomplete.
State R&D incentives are evolving into distinct programs with their own rules about where qualified research occurs, when a claim must be filed, how much funding is available, and whether the benefit can actually be converted into cash. As a result, a well-supported federal R&D credit may still leave meaningful state incentives unclaimed.
For multistate businesses, the question is no longer simply, “Do we qualify for the R&D credit?” The more useful questions are:
- Where was the research actually performed?
- Which states offer an economically meaningful benefit for that activity?
- What filing, certification or application requirements must be satisfied before the opportunity expires?
- Can the resulting credit be used, refunded or otherwise monetized?
That distinction increasingly matters as businesses operate across multiple jurisdictions and employees perform research from offices, laboratories, manufacturing facilities and remote locations.
The Federal Foundation: Understanding the R&D Credit
Two federal provisions anchor the federal R&D framework, but they address different aspects of the tax benefit.
1. Section 41 determines whether research activities qualify for the federal R&D credit. At the activity level, qualifying research generally must satisfy the federal four-part test:
- Permitted Purpose. The research must relate to the development or improvement of a business component, such as a product, process, technique, formula, invention or software, with the objective of improving its function, performance, reliability or quality.
- Elimination of Uncertainty. The activity must seek to resolve uncertainty regarding the capability, method or appropriate design for developing or improving the business component.
- Process of Experimentation. The taxpayer must evaluate one or more alternatives through a systematic process, such as modeling, simulation, testing or trial and error.
- Technological in Nature. The experimentation must fundamentally rely on principles of the physical or biological sciences, engineering, or computer science.
Together, these four requirements establish the federal qualification framework and identify the activities that may support an R&D credit claim.
2. Section 174 addresses the tax treatment of research spending. Recent federal changes restored immediate expensing for qualifying domestic research expenditures, improving the cash-flow benefit of U.S.-based R&D (Foreign R&E, however, generally continues to be amortized over 15 years.)
The distinction is straightforward: Section 41 determines whether the research may generate a credit while Section 174 affects how the underlying research costs are treated for tax purposes.
Federal treatment, however, does not resolve the state analysis. States can differ in their conformity to federal tax law and frequently impose their own R&D credit calculations, sourcing standards, application procedures, filing requirements and limitations.
The federal study therefore establishes a starting pool of potentially qualified activities and expenditures. The state analysis determines how those activities and expenditures are treated under the applicable state rules and what economic benefit may ultimately be available.
Beyond the Federal Return: How State R&D Credits Actually Work
Most states leverage the federal definition of QREs — in-house wages, supplies, certain computer-use costs, and contract research (generally includible at 65%) — but apply their own calculation methodologies, rates, and restrictions.
State R&D credits typically fall into one of three categories:
- Statutory/Entitlement Credits: Claimed directly on the state return (e.g., California).
- Refundable Credits: Allowing cash payouts for taxpayers in net operating loss (NOL) positions, though often subject to escalating percentages.
- Application-Based/Capped Pools: Requiring pre-certification or tentative claims months before the standard tax filing deadline.
Beyond these categories, some state programs layer on additional limits that shape the ultimate benefit, such as:
- Annual pool caps with proration (e.g., Florida prorates when applications exceed the cap).
- First-come certification (e.g., Hawaii’s $5 million annual cap).
- Fixed carryforward periods (e.g., Louisiana’s five-year carryforward under a $12 million fiscal-year cap).
- Non-transferability restrictions.
- Credit-ordering rules.
These features can be as decisive as the headline rate.
How States Are Reshaping Their R&D Credits
Michigan’s New Refundable R&D Credit
Michigan introduced a highly anticipated refundable R&D credit, which is now in effect. The credit equals 3% of QREs up to a base amount, plus 10% above the base for large employers (250 or more employees), capped at $2 million per taxpayer. Smaller employers earn 3% up to a base amount, plus 15% above the base, capped at $250,000. Research performed with a Michigan university adds another 5%, up to $200,000. The 250-employee threshold is a point-in-time test that can be affected by disregarded entities, professional employer organizations, and third-party payroll arrangements. Crucially, this is an application-based program subject to a $100 million statewide prorated cap — with $25 million reserved for smaller employers — that is prorated if oversubscribed. Tentative claims must be timely and based on actual, not estimated, QREs. Going forward, the annual submission deadline is generally March 15, following the close of each calendar year.
Iowa’s Transition to Pre-Certification
Iowa recently overhauled its program, replacing a far more generous system with a new, application-based structure administered by the Iowa Economic Development Authority (IEDA). Taxpayers must now be pre-certified as a qualified business and operate in designated sectors like advanced manufacturing or bioscience. Following pre-certification, the business must enter into an agreement, apply based on federal Form 6765 from its most recently filed federal return, and include verification from an Iowa CPA by January 31 of the following year. The credit offers up to 3.5% of eligible Iowa expenditures and remains partially refundable, but it is now capped statewide and reserved for targeted sectors — a sharp cut from Iowa’s former automatic, largely refundable credit.
Texas Rate Increases and Permanent Extension
Texas has permanently expanded both the calculation and potential value of the incentive. For qualifying taxpayers with the required history, the standard calculation can apply an 8.722% rate, increased to 10.903% for certain research conducted under contract with qualifying higher-education institutions. Different rates apply in certain situations when a taxpayer lacks qualifying expenditures in one or more of the preceding periods.
The credit generally cannot exceed 50% of franchise tax due, unused amounts carry forward for up to 20 consecutive reports, and the credit is not assignable except in connection with a transfer of substantially all of the taxpayer’s assets. That being said, certain businesses that owe no Texas franchise tax may now qualify for a refundable R&D credit, subject to statutory requirements, thus changing more than how the benefit is calculated but how it can be monetized.
Minnesota’s Accelerated Refundability
Minnesota continues to offer a credit calculated at 10% of the first $2 million of Minnesota QREs over the base amount, plus 4% of excess QREs above $2 million. QREs generally follow the federal definition but exclude research conducted outside Minnesota. The strategic value comes from its refundability provisions: up to 25% of the current-year credit that remains after tax liability is reduced to zero is refundable, making it a powerful cash-generation tool for pre-revenue tech and biotech taxpayers.
California’s Generous Credit, With a Usage Cap
California offers a statutory, nonrefundable credit — 15% of QREs over a base, plus 24% on basic-research payments — that carries forward indefinitely. The catch is usage, not eligibility: California has repeatedly capped the total business credits a taxpayer may use in a year, and proposals would make a version of that limit permanent. For companies with large California credits, the planning question becomes which years the credit can be used, so timing and modeling matter as much as the headline rate.
Pennsylvania Offers a Credit You Can Sell
Other states use transferability rather than direct refundability to help taxpayers monetize unused incentives.
Pennsylvania allows qualifying R&D tax credits to be sold, providing a potential path to value for businesses that cannot currently absorb the credit against their own tax liability. The program is subject to its own application and administrative requirements. The existing article appropriately recognizes that the opportunity can turn an otherwise deferred tax attribute into a more immediate economic benefit.
New Jersey takes a somewhat different approach. The state’s R&D credit itself is generally nonrefundable, but qualifying emerging technology and biotechnology businesses may be able to monetize unused tax attributes through a separate state transfer program.
The distinction is important:
The credit and the monetization mechanism are not always the same program.
For taxpayers, understanding both is necessary to determine the real economic value.
New Jersey: Cash for Pre-Profit Innovators
New Jersey pairs a 10% credit with an unusual monetization path. Its Technology Business Tax Certificate Transfer Program lets qualified, unprofitable technology and life-sciences companies sell unused R&D credits and net operating losses to profitable corporations for cash — generally around 80% or more of value, subject to a lifetime cap per business and an annual program pool. For a pre-revenue biotech burning cash, the program converts a paper benefit into runway.
Arizona’s High-Rate, Refundable Credit for Small Companies
Arizona offers one of the more generous first-tier rates — 24% on the first $2.5 million of QREs over a base, then 15% — and, uniquely, lets smaller companies (under 150 employees) receive up to 75% of the excess credit as a cash refund with advance approval from the Arizona Commerce Authority. Research conducted with a state university can provide additional benefits. The credit offers a rare combination of high rates and cash refundability, aimed at growing, not-yet-profitable companies.
Risk Considerations: When State R&D Credits Go Wrong
The State Cap Race and Missed Deadlines
As states move to application-based pools, the risk of missing a filing window creates exposure. A perfectly executed R&D study is worthless if tentative claim or certification deadlines are missed.
Federal Elections Can Have State Consequences
The federal Section 280C reduced-credit election does not reduce a taxpayer’s state R&D credit, but it may affect the state income-tax calculation. Because states differ in their conformity to federal research-expense and credit provisions, the same federal election can produce different results across jurisdictions. Multistate taxpayers should therefore evaluate the combined federal and state impact rather than making the election based on the federal benefit alone.
Audit Scrutiny on Geographic Sourcing
State revenue departments aggressively audit the physical location of R&E activities. Remote work environments have complicated this. A developer performing services in Nevada for a Texas-based company generally cannot have their wages included in the Texas QRE pool.
Rather than a single residence test, state credits require a state-specific sourcing analysis by QRE category. Louisiana, for example, sources wages to residents who perform services in Louisiana, supplies to those consumed in Louisiana, computer-use expenses to computers located in Louisiana, and contract research to services performed in Louisiana. Hawaii and Florida similarly exclude out-of-state research expenses. Payroll and expense records must therefore map to work location, service location, supply consumption, computer location, and contract-research performance — not merely employee residence.
Common State-level R&D Pitfalls: What Business Owners Often Miss
- A loss year is not a lost credit. Refundable states such as Arizona, Nebraska, and Minnesota — and sellable-credit states such as Pennsylvania, New Jersey, and Kansas — turn research spending into cash even when no tax is owed. Pre-revenue startups can also offset up to $500,000 of federal payroll taxes per year with the federal credit.
- The credit usually lands on your personal return. For S corporations, partnerships, and LLCs, state R&D credits typically flow through to the owners. As such, it’s essential to coordinate the entity and individual filings to prevent the benefit from becoming stranded.
- You can often look back. Many states let you amend open tax years to claim credits you missed, providing money for companies that have been performing qualifying work without ever filing a study.
- It becomes a diligence item when you sell. R&D credits and carryforwards are assets a buyer will scrutinize; thin documentation can turn into a purchase-price reduction.
- Documentation is the whole game. Contemporaneous, project-level records tied to where the work physically happened are what survive a state audit — spreadsheets rebuilt years later rarely suffice.
Your Takeaway
State R&D credits are not a label test tied to a federal study; they are a functional, territorial test focused on where the research actually happens and whether the claim clears each state’s deadline and conformity rules. Taxpayers who map their footprint, calendar every application window, and model the reduced credit election’s impact before finalizing the provision are positioned to convert the restored expensing deduction into real cash. The following steps should be built into every study:
1. Map
Identify where qualified employees, contractors, supplies, and research projects are physically located.
2. Screen
Evaluate the states in that footprint for credit eligibility, rates, caps, refundability, transferability and utilization restrictions.
3. Calendar
Identify every tentative-claim, certification, application and return deadline associated with those jurisdictions.
4.Model
Compare the federal and state tax consequences, including Section 280C elections, state conformity, available tax liability, refundability, carryforwards and expected cash realization.
The goal is not simply to calculate the largest theoretical credit; it is to identify the state R&D benefits that can actually be claimed, defended, and converted into economic value.
The state R&D landscape is becoming more fragmented at the same time that business-research footprints are becoming more geographically distributed.
That combination creates both opportunity and risk.
While a federal R&D study remains an important foundation, it should no longer be viewed as the complete answer for a multistate taxpayer. Businesses increasingly need a separate state strategy focused on geography, timing, and monetization.
Companies that map where research occurs, identify state filing requirements early and model the realizable value of available incentives are better positioned to capture the full benefit of their innovation spending.
Rehmann’s Specialty Tax Services team is actively helping multistate clients capture federal and state R&D credits. To make sure your credits are fully substantiated and every state deadline is met, click here to connect with our specialists.
Frequently Asked Questions
Does a federal R&D study automatically qualify us for state R&D credits?
No. A federal R&D study provides an important starting point, but state credits are governed by separate state law. States may differ in how they define or incorporate qualified research expenses, where the research must be performed, how the credit is calculated, and what filing or application requirements apply.
For multistate businesses, the federal study should therefore be used as the foundation for a separate state-by-state analysis.
The key takeaway: Federal qualification does not automatically produce a state credit.
What is the biggest mistake multistate businesses make with state R&D credits?
Treating the state credit as a simple extension of the federal R&D study.
A company can have a well-supported federal credit and still miss or materially reduce a state benefit because the research occurred outside the jurisdiction, a required application or certification deadline was missed, the program was subject to a statewide cap or proration, or the company could not currently utilize the resulting credit.
The better approach is to evaluate each relevant jurisdiction separately based on geography, eligibility, filing requirements and realizable value.
The key takeaway: Qualification is only the first step; the real objective is to identify credits that can actually be claimed, defended and realized.
How does remote or hybrid work affect state R&D credit eligibility?
It can materially affect the analysis.
State R&D credits generally focus on research performed within the applicable jurisdiction. As a result, the location of the employee or contractor performing the qualifying activity may matter more than the location of the company’s headquarters, payroll function or legal entity.
For businesses with remote or mobile research teams, payroll records alone may not establish the correct state sourcing. Companies should be able to connect qualifying activities and expenditures to the locations where the research was actually performed.
The key takeaway: Research location should be substantiated at the activity and expenditure level—not assumed from headquarters or payroll location.
What filing deadlines should businesses watch for?
Do not assume the income-tax return due date is the only deadline that matters.
Some state R&D programs require a separate application, tentative claim, certification or other filing before the standard return is filed. In capped or application-based programs, missing that procedural deadline can eliminate the benefit even when the underlying research otherwise qualifies.
For example, the article’s Michigan discussion highlights that the program has a separate application process and annual filing deadline, while Iowa also incorporates qualification and administrative requirements outside the ordinary return process.
The key takeaway: State R&D deadlines should be identified and calendared before the return-preparation process begins.
Is the state with the highest R&D credit rate necessarily the most valuable?
No.
Headline rates can be misleading if they are considered without the rest of the program. A higher-rate credit may be nonrefundable, subject to annual limitations, difficult to utilize or reduced through proration. A lower-rate credit may provide greater economic value if it is refundable, transferable or immediately usable against current tax liability.
Businesses should therefore evaluate the realizable value of the incentive, not just the statutory percentage.
The key takeaway: A smaller usable credit can be worth more than a larger credit that remains stranded for years.
What is the difference between a refundable, transferable and nonrefundable state R&D credit?
A refundable credit may generate a payment when the credit exceeds the taxpayer’s applicable tax liability, subject to the state’s specific rules.
A transferable credit may allow the taxpayer to sell or otherwise transfer the benefit to another taxpayer, again subject to state requirements.
A nonrefundable credit generally reduces tax liability but does not itself produce a cash refund. Unused amounts may be carried forward if the applicable state program permits it.
These distinctions can materially affect the timing and economic value of an R&D incentive.
The key takeaway: How a credit can be monetized can be as important as how the credit is calculated.
Can a company claim a state R&D credit if it is not currently profitable?
Potentially, yes—but the value depends on the state’s rules.
A company with little or no current tax liability may still benefit where a state offers refundability, transferability or another monetization mechanism. In other states, the credit may simply carry forward until sufficient tax liability exists.
That is why companies should distinguish between the credit generated and the benefit that can actually be realized in the current year.
The key takeaway: A loss year does not necessarily eliminate the opportunity, but it can materially change how and when the benefit is realized.
Can we amend prior-year returns to claim state R&D credits we missed?
Sometimes, but an open tax year does not automatically mean the credit remains available.
Return-based credits may be recoverable through an amended return if the applicable statute of limitations remains open. However, application-based or certification-based programs may impose separate deadlines that cannot necessarily be cured through an amended income-tax return.
Before pursuing historical claims, companies should confirm both the tax-return statute of limitations and any separate incentive-specific procedural requirements.
The key takeaway: An open return year and an open credit opportunity are not always the same thing.
How should pass-through entities approach state R&D credits?
Carefully and on a state-specific basis.
For partnerships, S corporations and other pass-through businesses, the credit may be claimed at the entity level, passed through or allocated to owners, applied against another state-level tax, or subject to special rules depending on the jurisdiction.
The entity and owner filings should therefore be coordinated to ensure the credit is reported and utilized consistently.
The key takeaway: Do not assume that state R&D credits follow the same pass-through treatment in every jurisdiction.
How important is documentation for state R&D credits?
It is critical to both qualification and defensibility.
Federal documentation should establish the qualifying research activities and related expenditures. State support must often go a step further by demonstrating where those activities occurred and how the associated wages, supplies, contractor costs and other eligible expenditures were sourced to the state.
For multistate and remote-work environments, contemporaneous project, payroll and location records can be particularly important.
The key takeaway: Strong state R&D documentation supports both what qualified and where it qualified.